お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
226022

HIV(ヒト免疫不全ウイルス)治療の世界市場:種類、製品、地域別 - 2019年~2023年の予測と分析

HIV (Human Immunodeficiency Virus) Therapeutics Market by Type, Product, and Geography - Forecast and Analysis 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 175 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
HIV(ヒト免疫不全ウイルス)治療の世界市場:種類、製品、地域別 - 2019年~2023年の予測と分析
出版日: 2019年10月10日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 175 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のHIV(ヒト免疫不全ウイルス)治療市場は、2019年から2023年の間に2%のCAGRで成長する見通しです。HIV治療の新薬の開発への取り組みや、HIVの流行に対する公衆衛生上の支援などが市場成長の要因に挙げられます。

当レポートはHIV(ヒト免疫不全ウイルス)治療市場について調査しており、市場動向、成長要因および課題、タイプ・製品・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • 前書き1
  • 前書き2
  • 米ドルの為替レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメント分析

第4章 市場規模

  • 市場の定義
  • 2018年の市場規模
  • 市場規模および予測2018-2023

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代用品の脅威
  • 業界内の競争
  • 市況

第6章 市場セグメント:タイプ別

  • 市場セグメント
  • 比較:市場規模・予測(2018年~2023年)
  • 併用療法
  • 単独療法
  • 市場機会

第7章 市場セグメント:製品別

第8章 顧客情勢

第9章 地域別情勢

  • セグメント
  • 比較:市場規模・予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因および課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

  • HIVの診断検査の進歩
  • 再生療法の研究開発
  • HIVワクチンの研究開発の増加

第13章 ベンダー情勢

  • 概要
  • 情勢の混乱
  • 競合のシナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場における位置づけ
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

第15章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第16章 テクナビオについて

図表

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of the global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Market segmentation by product: overview
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: AbbVie Inc. - Vendor overview
  • Exhibit 50: AbbVie Inc. - Business segments
  • Exhibit 51: AbbVie Inc. - Organizational developments
  • Exhibit 52: AbbVie Inc. - Geographic focus
  • Exhibit 53: AbbVie Inc. - Key offerings
  • Exhibit 54: AbbVie Inc. - Key customers
  • Exhibit 55: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 56: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 57: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 58: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 59: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 60: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 61: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 62: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 63: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 64: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 65: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 66: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 67: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 75: Gilead Sciences Inc. - Vendor overview
  • Exhibit 76: Gilead Sciences Inc. - Business segments
  • Exhibit 77: Gilead Sciences Inc. - Organizational developments
  • Exhibit 78: Gilead Sciences Inc. - Geographic focus
  • Exhibit 79: Gilead Sciences Inc. - Key offerings
  • Exhibit 80: Gilead Sciences Inc. - Key customers
  • Exhibit 81: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 82: GlaxoSmithKline Plc - Business segments
  • Exhibit 83: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 84: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 85: GlaxoSmithKline Plc - Segment focus
  • Exhibit 86: GlaxoSmithKline Plc - Key offerings
  • Exhibit 87: GlaxoSmithKline Plc - Key customers
  • Exhibit 88: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 89: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 90: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 91: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 92: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 93: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 94: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 95: Lupin Ltd. - Vendor overview
  • Exhibit 96: Lupin Ltd. - Business segments
  • Exhibit 97: Lupin Ltd. - Organizational developments
  • Exhibit 98: Lupin Ltd. - Geographic focus
  • Exhibit 99: Lupin Ltd. - Key offerings
  • Exhibit 100: Lupin Ltd. - Key customers
  • Exhibit 101: Merck & Co. Inc. - Vendor overview
  • Exhibit 102: Merck & Co. Inc. - Business segments
  • Exhibit 103: Merck & Co. Inc. - Organizational developments
  • Exhibit 104: Merck & Co. Inc. - Geographic focus
  • Exhibit 105: Merck & Co. Inc. - Segment focus
  • Exhibit 106: Merck & Co. Inc. - Key offerings
  • Exhibit 107: Merck & Co. Inc. - Key customers
  • Exhibit 108: Mylan NV - Vendor overview
  • Exhibit 109: Mylan NV - Product segments
  • Exhibit 110: Mylan NV - Organizational developments
  • Exhibit 111: Mylan NV - Geographic focus
  • Exhibit 112: Mylan NV - Segment focus
  • Exhibit 113: Mylan NV - Key offerings
  • Exhibit 114: Mylan NV - Key customers
  • Exhibit 115: Pfizer Inc. - Vendor overview
  • Exhibit 116: Pfizer Inc. - Business segments
  • Exhibit 117: Pfizer Inc. - Organizational developments
  • Exhibit 118: Pfizer Inc. - Geographic focus
  • Exhibit 119: Pfizer Inc. - Segment focus
  • Exhibit 120: Pfizer Inc. - Key offerings
  • Exhibit 121: Pfizer Inc. - Key customers
  • Exhibit 122: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 124: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 125: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 128: Validation techniques employed for market sizing
  • Exhibit 129: Definition of market positioning of vendors
目次
Product Code: IRTNTR32179

About this market

Technavio's HIV therapeutics market analysis considers sales from both combination therapy and monotherapy types. Our report also finds the sales of HIV therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficiency in the treatment of HIV will play a vital role in the combination therapy segment to maintain its market position. Also, our global HIV therapeutics market report looks at factors such as the growing awareness about HIV and the increasing number of initiatives to end the HIV epidemic, increasing funding, and approval of drugs, and strong pipeline. However, social stigma associated with HIV infection, high cost of antiretroviral therapies, and rising drug resistance may hamper the growth of the HIV therapeutics industry over the forecast period.

Overview

Growing awareness about HIV and an increasing number of initiatives to end the HIV epidemic

Various government organizations around the world are focusing on creating awareness about the development of novel medicines for the treatment of HIV. As a result, they are producing numerous initiatives such as Let's Stop HIV, Stop HIV, Start Talking, and Stop HIV Stigma. They are also supporting the public health response to the global HIV epidemic. Such initiatives and support are not only minimizing the annual incidence of HIV infection but also boosting the demand for HIV therapeutics among patients and healthcare units. Such factors will lead to the expansion of the global HIV therapeutics market at a CAGR of almost 2% during the forecast period.

Advances in diagnostic testing for HIV

A significant shift is observed from traditional laboratory testing for HIV, such as enzyme-linked immunosorbent assay (ELISA), saliva tests, and viral load test, to rapid point-of-care (POC) testing. POC HIV testing is the most accepted method. This method has been implemented to overcome some of the patient and provider barriers to routine screening. The preference for self-testing for HIV has been rapidly growing across developed countries. The home HIV test kit or HIV self-testing in a home setting marks the presence of HIV-1/2 antibodies or HIV-1 p24 antigen. The outcome of POC testing is improved by the development of sensors, microsystems, and low-cost imaging technologies. The market has also witnessed the development of mobile HIV diagnostic tools that revolutionize the detection of HIV in developing countries. Such advancements in diagnostic testing for HIV will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global HIV therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few significant players, the global HIV therapeutics market is moderately concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading HIV therapeutics manufacturers, that include AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Also, the HIV therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: MARKET SEGMENTATION BY PRODUCT

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Advances in diagnostic testing for HIV
  • R&D of regenerative therapies
  • Increasing R&D of HIV vaccines

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.